Full Press Release Details
Dogwood Therapeutics Reports
Second Quarter 2025 Financial Results
- Enrollment to-date of 52 patients in the ongoing Halneuron Phase 2b Trial -
- Halneuron Chemotherapy-Induced Neuropathic Pain ("CINP") Phase 2b study interim data readout remains on track for Q4 2025 -
- Low discontinuation rate (5.8%) due to adverse events in the first 38 patients completing the trial suggests Halneuron and placebo treatment have been generally well tolerated -
- Cash on hand of $13.4 million provides operational runway through Q1 2026 -
ATLANTA, Ga., August 13, 2025 -- Dogwood Therapeutics, Inc. (Nasdaq: DWTX) (the "Company"), a development-stage biotechnology company developing new medicines to treat pain and fatigue-related disorders, today announced financial results for the second quarter ended June 30, 2025.
"With no FDA approved treatments to manage the neuropathic pain often resulting from chemotherapy treatment, we have the opportunity to potentially enjoy the benefits of being the first and only approved CINP treatment," said Greg Duncan, Chief Executive Officer of Dogwood Therapeutics. "Further, we believe Halneuron's clinically significant effects in treating both general cancer pain and chemotherapy induced neuropathic pain highlights the significant potential to expand our NaV 1.7 research pipeline to other forms of pain, including diabetic peripheral neuropathy, post herpetic neuralgia and acute surgical pain."
"The NaV 1.7 sodium channel plays a fundamental role in pain transmission, so modulation of this pathway is likely to be applicable to the treatment of both chronic and acute pain states" said Michael Gendreau, MD, PhD, Chief Medical Officer of Dogwood Therapeutics. "A genetic lack of functioning NaV 1.7 channels leads to a condition known as Congenital Insensitivity to Pain Syndrome, a disorder characterized by the inability to feel pain. Patients who suffer from this condition illustrate the critical role NaV 1.7 function represents as a pain treatment target."
Dogwood Therapeutics Proprietary Pipeline Includes:
Second Quarter 2025 Financial Results
Research and development expenses for the second quarter of 2025 were $2.5 million, compared to $0.3 million for the second quarter of 2024. The $2.2 million increase quarter over quarter was primarily due to the impact of the business combination with Pharmagesic (the "Combination") including increases in expenses for clinical trials of $1.6 million related to the Halneuron CINP Phase 2b study, as well as drug development and manufacturing costs of $0.5 million and salaries and related personnel costs of $0.2 million, offset by a decrease in regulatory costs of $0.1 million.
General and administrative expenses for the second quarter of 2025 were $1.3 million, compared to $0.7 million for the second quarter of 2024. The $0.6 million increase quarter over quarter was primarily due to increases in legal and accounting fees of $0.2 million, salaries and related personnel costs of $0.2 million, expenses associated with being a public company of $0.1 million and other general and administrative costs of $0.1 million.
Net loss attributable to common stockholders for the second quarter of 2025 was $3.8 million, or $1.99 basic and diluted net loss per share, compared to a net loss attributable to common stockholders of $1.0 million, or $1.15 basic and diluted net loss per share, for the second quarter of 2024.
About Dogwood Therapeutics
Dogwood Therapeutics (Nasdaq: DWTX) is a development-stage biopharmaceutical company focused on developing new medicines to treat pain and fatigue-related disorders. The Dogwood research pipeline includes two separate mechanistic platforms with a non-opioid analgesic program and an antiviral program. The proprietary, non-opioid, NaV 1.7 analgesic program is centered on our lead development candidate, Halneuron , which is a highly specific voltage-gated sodium channel modulator, a mechanism known to be effective for reducing pain transmission. In clinical studies, Halneuron treatment has demonstrated pain reduction in pain related to general cancer and in pain related to chronic chemotherapy-induced neuropathic pain ("CINP"). Interim data from the ongoing Halneuron Phase 2 CINP study are expected in Q4 of 2025.
Dogwood's antiviral program includes IMC-1 and IMC-2, which are novel, proprietary, fixed-dose combinations of anti-herpes antivirals and the anti-inflammatory agent celecoxib. These combination antiviral approaches are being applied to the treatment of illnesses believed to be related to reactivation of previously dormant herpesviruses, including fibromyalgia ("FM") and Long-COVID ("LC"). IMC-1 is poised to progress into Phase 3 development as a treatment for FM and is the focus of external partnership activities. IMC-2 has been assessed in both active control and double-blind, placebo-controlled clinical trials and, in both cases, demonstrated successful reduction of the fatigue associated with LC. The company has reached an agreement with FDA on using reduction in fatigue as the primary endpoint for future IMC-2 LC research.
For more information, please visit www.dwtx.com.
Forward-Looking Statements:
Statements in this press release contain "forward-looking statements," within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as "anticipate," "believe," "contemplate," "could," "estimate," "expect," "intend," "seek," "may," "might," "plan," "potential," "predict," "project," "suggest," "target," "aim," "should," "will," "would," or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on Dogwood's current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict, including risks related to the completion, timing and results of current and future clinical studies relating to Dogwood's product candidates. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are
described more fully in the section titled "Risk Factors" in the Annual Report on Form 10-K for the year ended December 31, 2024, which has been filed with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date, and Dogwood undertakes no duty to update such information except as required under applicable law.
-Financial Tables Follow-
DOGWOOD THERAPEUTICS
Selected Financial Data
| Condensed Statements of Operations Data | Three Months Ended June 30, | Six Months Ended June 30, | ||||||||||||||
| 2025 | 2024 | 2025 | 2024 | |||||||||||||
| Revenue | $ | - | $ | - | $ | - | $ | - | ||||||||
| Operating expenses: | ||||||||||||||||
| Research and development | 2,569,943 | 336,084 | 5,006,941 | 679,801 | ||||||||||||
| General and administrative | 1,353,172 | 733,740 | 3,346,100 | 1,704,124 | ||||||||||||
| Total operating expenses | 3,923,115 | 1,069,824 | 8,353,041 | 2,383,925 | ||||||||||||
| Loss from operations | (3,923,115 | ) | (1,069,824 | ) | (8,353,041 | ) | (2,383,925 | ) | ||||||||
| Other (expense) income: | ||||||||||||||||
| Loss on debt conversion with related party | - | - | (6,134,120 | ) | - | |||||||||||
| Interest income (expense), net | 111,379 | 19,991 | (35,711 | ) | 42,757 | |||||||||||
| Exchange gain (loss), net | 4,532 | - | (18,742 | ) | - | |||||||||||
| Total other income (expense), net | 115,911 | 19,991 | (6,188,573 | ) | 42,757 | |||||||||||
| Loss before income taxes | (3,807,204 | ) | (1,049,833 | ) | (14,541,614 | ) | (2,341,168 | ) | ||||||||
| Deferred income tax provision | (149 | ) | - | (190,691 | ) | - | ||||||||||
| Net Loss | (3,807,353 | ) | (1,049,833 | ) | (14,732,305 | ) | (2,341,168 | ) | ||||||||
| Accrual of paid-in-kind dividends on Series A non-voting convertible preferred stock | - | - | (1,256,662 | ) | - | |||||||||||
| Net loss attributable to common stockholders | $ | (3,807,353 | ) | $ | (1,049,833 | ) | $ | (15,988,967 | ) | $ | (2,341,168 | ) | ||||
| Net loss per share of common stock - basic and diluted | $ | (1.99 | ) | $ | (1.15 | ) | $ | (9.51 | ) | $ | (2.78 | ) | ||||
| Weighted average shares outstanding - basic and diluted | 1,911,128 | 916,031 | 1,680,827 | 843,174 |
| Condensed Consolidated Balance Sheet Data | June 30, | December 31, | |||||
| 2025 | 2024 | ||||||
| Cash | $ | 13,402,809 | $ | 14,847,949 | |||
| Total assets | 96,692,527 | 94,308,246 | |||||
| Total liabilities | 14,151,904 | 30,027,223 | |||||
| Total stockholders' equity (deficit) | 6,878,599 | (10,124,339 | ) |
Source: Dogwood Therapeutics, Inc.